Протокол спостереження після орхіектомії при герміногенній пухлині яєчка I стадії — маркери, КТ та ризик рецидиву без ад'ювантної терапії
Testicular germ cell tumors (GCTs) are the most common solid malignancy in men aged 15–35, yet cure rates exceed 95% overall. Treatment begins with inguinal radical orchiectomy — the specimen is then staged by pathology, tumor markers, and CT. Roughly 70–80% of patients present as Clinical Stage I (CS1): disease confined to the testis with no radiographic or biochemical evidence of spread. For these patients, active surveillance — not routine adjuvant therapy — is now the guideline-preferred management.
Diagnosis and initial treatment are inseparable: any suspicious testicular mass undergoes radical inguinal orchiectomy (never a scrotal/transscrotal approach, which risks altering lymphatic drainage and local seeding). The specimen provides:
• Histologic subtype: pure seminoma vs. non-seminomatous germ cell tumor (NSGCT — embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, or mixed) • Tumor size and rete testis invasion (seminoma-specific risk factors) • Lymphovascular invasion (LVI) — the dominant adverse prognostic factor for NSGCT • Percentage embryonal carcinoma component — a secondary NSGCT risk factor • Margin status of the spermatic cord
Clinical Stage I is assigned when post-orchiectomy imaging (CT abdomen/pelvis, chest imaging) shows no metastasis and tumor markers either were never elevated or have normalized according to expected half-life kinetics.
Not all CS1 patients carry equal risk. Two parallel but distinct risk schemes exist:
Seminoma CS1: • Tumor size >4 cm • Rete testis invasion Presence of neither factor: ~12% 5-year relapse risk on surveillance. Presence of both: relapse risk rises toward ~20–32% in some series — still low enough that surveillance remains guideline-preferred for most patients given salvage is highly effective.
Non-seminoma CS1: • Lymphovascular invasion (LVI) is the single strongest predictor — raises 5-year relapse risk from ~14–20% (LVI-negative) to ~40–50% (LVI-positive) • Predominant embryonal carcinoma component is a secondary factor
These factors do not mandate treatment — they inform a shared decision between surveillance (with intensified monitoring in higher-risk patients), one cycle of adjuvant BEP chemotherapy, or (seminoma only) adjuvant carboplatin/radiotherapy.
Even LVI-positive non-seminoma patients managed with surveillance alone achieve near-100% eventual cure when relapse is caught early and treated with salvage chemotherapy — surveillance is not a lower-cure-rate strategy, only a delayed-treatment-in-a-minority strategy.
Through the 1980s–1990s, adjuvant retroperitoneal lymph node dissection, radiotherapy, or chemotherapy was routine for CS1 disease — treating every patient to prevent relapse in the roughly 15–30% who would eventually relapse, and over-treating the 70–85% who never would.
Long-term cohort data (Princess Margaret Hospital, Danish Testicular Cancer Study Group, and others, each with >15 years follow-up) demonstrated that surveillance — deferring further treatment until relapse is detected — achieves equivalent cancer-specific survival (~99%) while avoiding the surgical morbidity, secondary malignancy risk, cardiovascular toxicity, and infertility risk of routine adjuvant treatment.
Surveillance is now the preferred strategy in NCCN, EAU, and ESMO guidelines for most CS1 patients regardless of risk factors, with adjuvant therapy reserved for patients who decline intensive follow-up or have very high-risk features.
Testicular GCTs are among the few solid tumors with reliable, quantitative serum biomarkers. Alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) are secreted by specific histologic components and decline predictably after complete tumor removal — their kinetics (not just their absolute value) are the diagnostic tool. A marker that fails to fall on schedule signals persistent disease even before it is visible on any scan.
• AFP (alpha-fetoprotein): produced by yolk sac (endodermal sinus) tumor elements and some embryonal carcinoma. Elevated AFP in a testicular tumor effectively rules out pure seminoma — any AFP elevation reclassifies management as non-seminoma pathway regardless of histology report.
• β-hCG: produced by syncytiotrophoblastic giant cells, present in choriocarcinoma and, to a lesser extent, embryonal carcinoma and even ~15–20% of pure seminomas (mild elevation, typically <200 mIU/mL). Markedly elevated hCG (>5,000–10,000) suggests a choriocarcinoma component and higher-volume disease.
• LDH: nonspecific but correlates broadly with tumor burden and is part of the IGCCCG (International Germ Cell Cancer Collaborative Group) risk classification used once metastatic disease is diagnosed; in CS1 surveillance it is a supportive adjunct rather than a primary decision-driver.
A single post-op marker value is easy to misinterpret. What confirms complete resection is whether the marker falls along its expected exponential decay curve:
AFP(t) = AFP₀ × 0.5^(t / 5–7 days) β-hCG(t) = hCG₀ × 0.5^(t / 24–36 hr)
Given β-hCG's short half-life, a normal level is expected within roughly 1–2 weeks after orchiectomy if disease was fully resected. AFP, with its much longer half-life, may take 4–6 weeks to normalize even after complete resection — a mildly elevated AFP at 2 weeks post-op is not automatically abnormal.
A marker that plateaus, rises, or falls slower than its expected half-life — even while still numerically "within range" for its trajectory — is the earliest possible signal of residual or metastatic disease, often preceding any visible abnormality on CT by weeks.
Because β-hCG clears in days and AFP over weeks, the two markers together create a layered surveillance signal: hCG gives near-real-time confirmation of complete early clearance, while AFP kinetics remain informative for a longer post-operative window.
After initial normalization, markers are rechecked at every surveillance visit for the full follow-up duration (typically 5 years, sometimes 10 for higher-risk patients). A secondary rise in AFP and/or β-hCG during surveillance — even before imaging shows a lesion — is one of the two principal relapse-detection tools, alongside CT.
Importantly, roughly 20–30% of non-seminoma relapses and the large majority of seminoma relapses are marker-negative — meaning cross-sectional imaging remains essential and cannot be replaced by bloodwork alone. Marker and imaging surveillance are complementary, not interchangeable.
Surveillance imaging is deliberately front-loaded: scan frequency is highest in year 1–2, when the overwhelming majority of relapses occur, and tapers substantially by year 3–5. This risk-adapted design — rather than a flat fixed interval for 5 years — balances early relapse detection against cumulative radiation exposure in a population of young, otherwise-healthy men with a multi-decade life expectancy.
Surveillance protocols are not arbitrary — they are fit to the empirical hazard curve of relapse timing. Because ~70–90% of relapses occur within the first 2 years, imaging is concentrated there; because late relapse beyond year 5 is rare (well under 5%), most guidelines stop routine imaging at 5 years.
Modality choice also matters: CT abdomen/pelvis is the primary modality for detecting retroperitoneal lymphadenopathy (the dominant relapse site). For the chest, low-dose plain radiography (CXR) is preferred over routine CT chest for most low-risk patients, since pulmonary-only relapse without retroperitoneal or marker abnormality is uncommon, and this substantially reduces cumulative radiation exposure.
Patients with CS1 testicular cancer are typically in their 20s–30s with a normal life expectancy after cure — meaning cumulative diagnostic radiation exposure over a 5-year (or longer) surveillance course is a genuine long-term consideration, not a theoretical one.
Modern protocols address this by: • Reducing total CT scan count per protocol revision (successive NCCN/EAU updates have progressively thinned the schedule as outcome data matured) • Preferring CXR over CT chest when retroperitoneal and marker surveillance is reassuring • Considering MRI abdomen/pelvis (non-ionizing) as an institution-dependent alternative to CT in some centers • Stopping routine imaging at year 5 given the low yield of later scans
This reflects a broader shift in surveillance oncology: matching test intensity to actual event-hazard, rather than applying uniform intensity across the entire follow-up window.
A full 5-year non-seminoma low-risk CT schedule can involve on the order of 5–7 abdominal/pelvic CT scans versus 10+ under older fixed-interval protocols — a meaningful reduction in lifetime radiation burden for a population with decades of life expectancy remaining.
Clinic visits with history, physical exam, and tumor markers occur more frequently than imaging — typically every 2–3 months in year 1, spacing out to every 6–12 months by year 4–5. This layered design means markers are checked far more often than scans, catching many relapses biochemically between imaging time points, while CT captures marker-negative relapses that bloodwork alone would miss.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Seminoma — Low risk | Year 1: visits/markers q3–4mo; Year 2: q4–6mo | CT abd/pelvis: yr1 ~2 scans, yr2 1 scan, yr3–5 annual or biennial | ~12% 5-yr relapse; lightest schedule |
| Seminoma — High risk (>4cm and/or rete testis+) | Year 1: visits/markers q3mo; Year 2: q4mo | CT abd/pelvis: yr1 2–3 scans, yr2 2 scans, yr3–5 annual | ~16–20% 5-yr relapse; modestly intensified |
| Non-seminoma — Low risk (LVI−) | Year 1: visits/markers q2mo; Year 2: q3mo | CT abd/pelvis: yr1 2 scans, yr2 1–2 scans, yr3–5 annual | ~14–22% 5-yr relapse |
| Non-seminoma — High risk (LVI+) | Year 1: visits/markers monthly–q2mo | CT abd/pelvis: yr1 3–4 scans, yr2 2–3 scans, yr3–5 annual, consider extending to yr10 | ~40–50% 5-yr relapse; most intensive monitoring, or offered 1 cycle adjuvant BEP |
When relapse occurs during surveillance, it follows a highly predictable pattern in both anatomic location and timing. Recognizing this pattern is exactly what allows the surveillance schedule to be front-loaded and site-focused rather than uniform: nearly all relapses are found where — and roughly when — the protocol is designed to look.
The testis drains lymphatically along the gonadal vessels directly to the para-aortic and paracaval retroperitoneal lymph nodes at the level of the renal hilum — not to the pelvic or inguinal nodes (which would only be involved if scrotal violation altered normal drainage). This anatomically predictable first echelon of spread is precisely why CT abdomen/pelvis, not chest or pelvis-only imaging, is the cornerstone surveillance study.
Beyond the retroperitoneum, the next most common relapse sites are the lungs (hematogenous spread, more common with choriocarcinoma component) and, less frequently, mediastinal nodes, liver, brain, or bone — reasons a baseline and periodic chest evaluation remains part of the protocol even though it is not the dominant site.
Relapse risk is not constant over the 5-year surveillance window — it is heavily front-weighted:
• Year 1: highest hazard period, particularly months 4–15 • Year 2: risk continues but at a substantially lower rate • Years 3–5: risk falls further, though non-seminoma (especially LVI+) can still relapse into year 3–4 • Beyond year 5: rare (a small minority of relapses, sometimes representing a second primary rather than true late relapse of the original tumor)
This hazard curve is the direct evidentiary basis for front-loading both marker checks and CT scans into year 1–2, and for the option to de-intensify or stop surveillance by year 5 in most protocols.
Relapse timing differs slightly by histology: non-seminoma relapses tend to cluster earlier (median roughly 6–12 months) than seminoma relapses, which can present somewhat later (median closer to 12–18 months) — one reason seminoma surveillance windows sometimes extend monitoring further into year 2–3.
Relapse is identified through one of two complementary signals, and sometimes both simultaneously:
1. Biochemical: a marker (AFP and/or β-hCG) that was normal begins rising on a scheduled surveillance blood draw, prompting an unscheduled CT to localize disease.
2. Radiographic: a new or enlarging retroperitoneal lymph node (generally a short-axis threshold around 1 cm, or clear interval growth of a smaller node) is identified on a scheduled surveillance CT, even with normal markers — accounting for the marker-negative relapse subset.
Most relapses are low-volume at detection (a small number of enlarged retroperitoneal nodes, or a modest marker elevation) precisely because the surveillance interval is short enough to catch disease before it becomes bulky — which is itself a major reason salvage treatment succeeds so reliably.
The ultimate justification for surveillance is outcome equivalence at lower population-level toxicity. Testicular GCT is exquisitely chemosensitive — even when relapse occurs, salvage chemotherapy (typically 3–4 cycles of BEP: bleomycin, etoposide, cisplatin) cures the overwhelming majority of patients. Surveillance exploits this chemosensitivity to defer treatment — and its side effects — to only the minority who actually need it.
Randomized and large cohort comparisons of surveillance versus routine adjuvant chemotherapy or radiotherapy in CS1 disease consistently show no meaningful difference in overall or cancer-specific survival — both approaches converge on cure rates near 99% because relapsed disease remains so treatable.
What differs sharply is toxicity exposure at the population level. Routine adjuvant treatment exposes 100% of patients to therapy-related risk to prevent relapse in only the 15–50% (depending on histology/risk) who would ever relapse. Surveillance inverts this: it exposes only the fraction who actually relapse to chemotherapy, while the majority who never relapse are exposed to nothing beyond the original orchiectomy.
Adjuvant chemotherapy (even a single cycle of BEP) and adjuvant radiotherapy (historically used for seminoma) each carry measurable long-term risks in a population expected to live many decades post-treatment:
• Secondary malignancy: cumulative alkylating/platinum exposure and radiotherapy both carry a small but real long-term second-cancer risk • Cardiovascular toxicity: cisplatin-based chemotherapy is associated with elevated long-term cardiovascular event rates • Nephrotoxicity and ototoxicity: cisplatin dose-dependent, cumulative • Pulmonary toxicity: bleomycin-associated pulmonary fibrosis, uncommon but serious • Infertility and gonadal toxicity: compounding the fact that many patients already have baseline subfertility associated with GCT
By reserving these exposures for the minority who relapse, surveillance meaningfully reduces population-level long-term morbidity without sacrificing cure rate.
Because salvage chemotherapy for relapsed CS1 disease uses essentially the same regimen (BEP) that would have been given as adjuvant therapy, a patient managed on surveillance who ultimately relapses is not receiving "extra" or different treatment — they are simply receiving the identical treatment later, and only if actually needed.
Surveillance is only appropriate when three conditions hold, all of which are true for CS1 testicular cancer:
1. Relapse, if it occurs, is reliably detectable early (predictable anatomic site, quantitative biomarkers, defined temporal window) 2. Relapsed disease remains highly curable with standard salvage therapy (chemosensitivity does not meaningfully decline with a several-month treatment delay) 3. Patients can be relied upon to adhere to the follow-up schedule (a genuine clinical consideration — non-adherence is the main practical argument in favor of adjuvant therapy in select patients)
When these hold, deferring treatment until relapse is objectively demonstrated is a rational, guideline-endorsed strategy — and testicular cancer surveillance is often cited as the model system demonstrating that "watch and treat only if needed" can match "treat everyone up front" without compromising cure.